Knight Therapeutics (TSE:GUD) Sets New 52-Week High – What’s Next?

Knight Therapeutics Inc. (TSE:GUD) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as C$9.51 and last traded at C$9.46, with a volume of 62054 shares changing hands. The stock had previously closed at C$9.48.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group set a C$9.50 price objective on Knight Therapeutics and gave the company a “buy” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of C$9.50.

Knight Therapeutics Stock Performance

The company has a 50-day moving average price of C$8.08 and a two-hundred day moving average price of C$6.83. The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86. The stock has a market capitalization of C$930.74 million, a P/E ratio of 158.00, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.14.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, May 7th. The company reported C$0.13 EPS for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%.The business had revenue of C$147.59 million during the quarter. On average, equities analysts forecast that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.